This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Institut Pasteur Korea, Korea Institute of Radiological & Medical Sciences. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2026
Title: Yeonhwa Song: Innovator in Medical Applications of 2-Methoxyestradiol Derivatives
Introduction
Yeonhwa Song is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of medical science, particularly through his innovative work on 2-methoxyestradiol derivatives. His research focuses on the treatment and prevention of liver and lung fibrosis, showcasing his commitment to advancing medical knowledge and therapeutic options.
Latest Patents
Yeonhwa Song holds a patent for "2-methoxyestradiol derivatives and medical uses thereof." This invention relates to novel derivatives that are particularly useful in treating or preventing liver or lung fibrosis. The patent outlines a method of administering an effective amount of these derivatives to achieve therapeutic benefits. This innovative approach has the potential to impact the treatment landscape for patients suffering from these conditions.
Career Highlights
Throughout his career, Yeonhwa Song has worked with esteemed institutions such as Institut Pasteur Korea and the Korea Institute of Radiological & Medical Sciences. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Yeonhwa Song's notable coworkers include Haeng Ran Seo and Inhee Choi. Their collaborative efforts have further enriched the research environment and fostered innovation in medical applications.
Conclusion
Yeonhwa Song's work on 2-methoxyestradiol derivatives exemplifies the intersection of innovation and medical science. His contributions have the potential to significantly improve treatment options for liver and lung fibrosis, highlighting the importance of continued research and development in this area.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile